mevalonic acid has been researched along with Diabetic Glomerulosclerosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Danesh, FR; Kanwar, YS | 1 |
| Adler, S; Chew, TL; Danesh, FR; Eng, E; Kanwar, YS; Sadeghi, MM; Xu, H; Zeng, L | 1 |
| Han, DC; Kim, SI; Lee, HB | 1 |
1 review(s) available for mevalonic acid and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cholesterol; Diabetic Angiopathies; Diabetic Nephropathies; Endothelium, Vascular; Enzyme Induction; GTP Phosphohydrolases; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Insulin Resistance; Mevalonic Acid; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Oxidative Stress; Protein Prenylation; Protein Processing, Post-Translational; Rabbits; Rats; Rhabdomyolysis; Signal Transduction; Terpenes | 2004 |
2 other study(ies) available for mevalonic acid and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation.
Topics: Actins; Animals; Blotting, Western; Cell Line; Cytoplasm; Cytoskeleton; Cytosol; Diabetic Nephropathies; Electric Impedance; Endothelial Cells; Endothelium, Vascular; Green Fluorescent Proteins; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Glomerulus; Mevalonic Acid; Microscopy, Confocal; Models, Biological; Models, Statistical; Myosin Light Chains; Permeability; Phosphorylation; Rats; rhoA GTP-Binding Protein; Signal Transduction; Simvastatin; Transfection; Vascular Endothelial Growth Factor A | 2005 |
Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells.
Topics: Albuminuria; Animals; Blood Glucose; Cells, Cultured; Cholesterol; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Fibronectins; Glomerular Mesangium; Kidney Glomerulus; Lovastatin; Male; Mevalonic Acid; Organ Size; Protein Biosynthesis; Rats; Rats, Sprague-Dawley; RNA, Messenger; Streptozocin; Transforming Growth Factor beta | 2000 |